SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The filing discloses a declaration of distributions to stockholders across seven classes of common stock, with specific per-share amounts ranging from $0.0753 to $0.1123 (gross), payable on or about July 20, 2026. This is a routine but material dividend distribution disclosure typical of real estate investment trusts (REITs), which are required to distribute substantially all taxable income to shareholders.
View raw filing on EDGAR →ALX Oncology appointed Scott Garland as Chairman of the Board (effective June 29, 2026) and Michael Listgarten as General Counsel (effective immediately), representing a significant governance transition. Corey Goodman, co-founder, stepped down as Chairman after more than a decade of leadership.
View raw filing on EDGAR →Bilibili announced an update on its two-year US$300 million share repurchase program adopted in June 2026. As of June 30, 2026, the company had repurchased 4.8 million shares for approximately US$100.1 million in the six-month period, representing a material return of capital to shareholders.
View raw filing on EDGAR →XCharge received a written notice from Nasdaq on June 24, 2026, that it failed to meet the minimum bid price requirement (closing bid price below $1.00 per ADS for 30 consecutive business days). The company has 180 calendar days until December 21, 2026, to regain compliance, and if it fails to do so, Nasdaq will provide notice of delisting. This is a classic delisting-risk disclosure under Item 3.01 equivalent, materially affecting the registrant's continued listing status.
View raw filing on EDGAR →Aptevo entered into a Grant Award Agreement with the Andy Hill Cancer Research Endowment (CARE) Fund for $1.5 million in non-dilutive research funding to support IND-enabling studies for APVO451, a trispecific antibody candidate. This material research partnership provides external validation and advances a strategic pipeline priority toward clinical development.
View raw filing on EDGAR →Ecovyst Inc. completed the acquisition of INEOS Calabrian Holdings Corp. and INEOS Calabrian Corporation Canada, Inc. for a $190 million purchase price pursuant to a Share Purchase Agreement dated May 1, 2026, through wholly owned subsidiaries.
View raw filing on EDGAR →Ecovyst Inc. entered into a Fourth Amendment to its existing Term Loan Credit Agreement on June 30, 2026, providing for an additional $100.0 million first lien term loan, with proceeds used to finance the INEOS Calabrian acquisition and general corporate purposes.
View raw filing on EDGAR →Apollo Debt Solutions BDC entered into a Seventh Supplemental Indenture on June 30, 2026, creating $750 million in aggregate principal amount of 6.350% notes due 2033, with net proceeds of approximately $736.7 million. This material debt issuance creates a new direct financial obligation that significantly affects the Fund's capital structure and leverage.
View raw filing on EDGAR →The 6-K discloses new radiographic data from Week 104 of the completed ApproaCH pivotal trial of TransCon CNP in children with achondroplasia, presented at an international conference. This represents a material clinical milestone—positive efficacy and safety data from a Phase 3 trial supporting a lead product candidate—but does not fit the discrete event categories (not an earnings release, M&A activity, executive change, or restatement). The disclosure is clearly operational/strategic (clinical trial results) rather than financial, governance, or legal, making operational_other the most appropriate classification.
View raw filing on EDGAR →Blackstone Real Estate Income Trust held its 2026 Annual Meeting of Stockholders on June 25, 2026, with detailed vote results reported for the election of eight directors and ratification of Deloitte & Touche LLP as independent auditor.
View raw filing on EDGAR →The company declared distributions to stockholders across multiple share classes on June 29, 2026, with per-share amounts ranging from $0.0451 to $0.0553 (net of servicing fees), payable on or about July 20, 2026, with reinvestment options available.
View raw filing on EDGAR →BlackRock Monticello Debt REIT amended its Master Repurchase Agreement with Natixis, increasing the maximum facility amount from $250 million to $500 million and extending the funding expiration date to June 24, 2028. This material expansion of the credit facility doubles the available borrowing capacity and extends the maturity of the financing arrangement.
View raw filing on EDGAR →The Company declared a monthly distribution to shareholders of BlackRock Monticello Debt REIT across three classes of common shares (Class F-S, F-I, and E) at $0.1927 per share gross, with a record date of June 30, 2026 and payment date of approximately July 21, 2026. This is a routine dividend distribution consistent with REIT distribution requirements.
View raw filing on EDGAR →Interactive Strength announced a 1-for-7 reverse stock split effective June 29, 2026, undertaken to regain compliance with the Nasdaq Capital Market's minimum bid price requirement of $1.00 per share and maintain its continued listing status. The reverse split was approved by stockholders on June 8, 2026 and finalized by the board on June 18, 2026 via charter amendment.
View raw filing on EDGAR →Disc Medicine entered into a First Amendment to its Loan and Security Agreement with Hercules Capital on June 25, 2026, drawing down $30,000,000 of Tranche 1-B Advance and restructuring existing tranches totaling $50,000,000, with extended drawdown periods for future tranches through 2028.
View raw filing on EDGAR →Talos Energy entered into a definitive purchase agreement on June 30, 2026, to acquire deepwater oil and gas properties in the Gulf of America (Na Kika and Coulomb fields) from Shell Offshore Inc. for $1.7 billion aggregate purchase price ($850 million net to Talos), adding 23 MMBoe of proved reserves and 16 MBoe/d of production, with expected close by end of 2026.
View raw filing on EDGAR →Talos amended its credit agreement to increase the borrowing base from $700 million to $850 million, adding $150 million in incremental commitments to fund the Gulf of America acquisition.
View raw filing on EDGAR →The Audit Committee dismissed CBIZ CPAs as the independent registered public accounting firm effective immediately on June 24, 2026, and approved the engagement of Grant Thornton LLP as the replacement auditor, effective immediately. This is a clear auditor change under Item 4.01, which is material to investors as it affects the registrant's financial reporting oversight and audit quality assurance.
View raw filing on EDGAR →The Company declared a regular distribution of $0.1847 per share to common shareholders, payable on or about July 30, 2026, with a record date of June 30, 2026 and payment options including cash or reinvestment in additional shares.
View raw filing on EDGAR →The Company disclosed a continuous private placement of Common Shares under Section 4(a)(2) and Regulation D, with approximately $4.8 million in subscriptions received on June 1, 2026, and an intention to continue monthly sales at NAV, representing an ongoing unregistered equity issuance that dilutes existing shareholders.
View raw filing on EDGAR →Fox Corporation entered into a $1.0 billion senior unsecured term loan credit agreement with Morgan Stanley and a syndicate of lenders on June 30, 2026, to finance a portion of the cash consideration for the Roku acquisition.
View raw filing on EDGAR →The Company declared a regular distribution of $0.1682 per Common Share and a special distribution of $0.0102 per Common Share, payable to shareholders of record as of June 30, 2026, with payment on or about July 30, 2026.
View raw filing on EDGAR →The Company is conducting a continuous private placement of Common Shares under Section 4(a)(2) and Regulation D, with approximately $2.5 million in subscriptions received on June 1, 2026, and an intention to continue monthly sales at NAV.
View raw filing on EDGAR →Mercer International announced an extension of a maintenance shutdown at its German pulp mill (Mercer Rosenthal) from two weeks to the entire month of September 2026. This is an operational/strategic business event involving a material production facility (360,000 tonnes annual kraft pulp capacity) that would affect investor assessment of near-term production and cash flow. While not fitting a specific named operational category, it is clearly operational in nature and material to a forest products company's performance.
View raw filing on EDGAR →The Company declared a regular distribution of $0.1824 per share to shareholders of record as of June 30, 2026, payable on or about July 30, 2026.
View raw filing on EDGAR →The Company disclosed material financial metrics including NAV per share of $24.66 as of May 31, 2026, aggregate NAV of $807.4 million, a debt-to-equity ratio of 1.16x, and continuous public offering status with $821.8 million raised through June 1, 2026.
View raw filing on EDGAR →Virginia Electric & Power Company issued 6,046 shares of common stock to its parent Dominion Energy for approximately $450 million in a transaction exempt from registration under Section 4(a)(2) of the Securities Act. This is a classic unregistered equity issuance disclosed under Item 3.02, and the $450 million proceeds used to reduce intercompany debt represent a material capital transaction that would affect a reasonable investor's assessment of the company's capital structure and leverage.
View raw filing on EDGAR →The filing discloses the appointment of Cynthia T. Jamison to Sunbelt Rentals' Board of Directors, effective August 1, 2026, along with her appointment to the Audit Committee. The principal disclosed action is a person taking a governance role. While the Board was expanded from eight to nine directors, the core event is the election and appointment of Ms. Jamison, a director with extensive board and executive leadership experience across major public companies (Darden, Advance Auto Parts, IFF) and financial expertise as a former CFO and CPA.
View raw filing on EDGAR →This Item 5.07 filing discloses the results of the 2026 annual meeting of stockholders held on June 26, 2026, including voting outcomes for two proposals: (1) election of two Class II directors (Shalini Sharp and Jake Simson) and (2) ratification of Ernst & Young LLP as independent auditor. The disclosure presents vote tallies (votes for, against, withheld, and broker non-votes) for each proposal, which is the core content of a shareholder vote results disclosure.
View raw filing on EDGAR →The filing discloses entry into two material definitive agreements: a Supply Agreement with Orion for manufacture and supply of the Oral Product (with a five-year initial term and automatic renewals), and a Sixth Amendment to the License Agreement extending the regulatory approval milestone to December 31, 2035. While these are contractual arrangements material to the Company's development and commercialization of its levosimendan product, they do not constitute a merger, acquisition, disposition, or change of control (ma_activity), nor do they fit other specific event categories. This is a material operational/strategic agreement that affects the Company's ability to develop and commercialize its product candidate.
View raw filing on EDGAR →Blue Owl Capital entered into a Third Amendment to its Senior Secured Revolving Credit Agreement on June 25, 2026, which materially modifies the company's existing credit facility by extending the revolver availability period to June 2030 and maturity date to June 2031, increasing the accordion provision to $6 billion, and resetting financial covenants. This material modification of a direct financial obligation affects the company's capital structure and liquidity position.
View raw filing on EDGAR →Blue Owl Capital terminated a $300 million secured credit facility on June 25, 2026, with full repayment of all outstanding obligations and release of liens. This material financial event affects the registrant's capital structure and available liquidity.
View raw filing on EDGAR →Seadrill Finance Limited issued $700 million in aggregate principal amount of 6.750% Senior Notes due 2034 pursuant to an Indenture dated June 30, 2026, and used proceeds to redeem approximately $575 million of 2030 Notes. The company also amended its Senior Secured Revolving Credit Agreement to increase commitments from $225 million to $300 million, effective June 30, 2026.
View raw filing on EDGAR →Spire Inc. completed the sale of all membership interests in Belle Butte LLC, which owns two natural gas storage subsidiaries in Wyoming and Oklahoma, to I Squared Capital for approximately $657 million in total consideration ($607 million cash at closing plus $50 million deferred payment). This material disposition of a significant business segment sharpens the company's strategic focus toward regulated utility operations.
View raw filing on EDGAR →The disclosure announces topline results from a Phase 1 clinical study of vamorolone (AGAMREE), demonstrating on-target glucocorticoid activity without significant immunosuppression at clinical doses. This is a material clinical milestone for a drug candidate that could support expansion into additional chronic inflammatory rare disease indications. While not a traditional earnings release (which reports financial results), this represents a significant operational/clinical development event that would affect investor assessment of the company's pipeline and commercial prospects.
View raw filing on EDGAR →R. Jason Richey resigned from the Board of Directors and his role as Audit Committee chairperson effective June 24, 2026. The disclosure centers on a director's departure from the board and a key committee leadership position. While the filing notes the resignation was not due to disagreement, the loss of an Audit Committee chair is material to investors assessing governance and financial oversight.
View raw filing on EDGAR →Lumexa Imaging entered into an amended credit agreement creating an $823 million replacement term loan and a $250 million revolving credit facility, both with specified interest rates and maturity dates, constituting material new direct financial obligations.
View raw filing on EDGAR →Nuvation Bio completed a $250 million registered public offering of 0.75% Convertible Senior Notes due 2032 on June 30, 2026, with an additional $37.5 million over-allotment option. The company used net proceeds of approximately $241.2 million to repay its senior secured loan agreement and for general corporate purposes, effectively refinancing its prior debt facility.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Devon Energy's 2026 Annual Meeting of Stockholders held on June 30, 2026. The filing presents voting tabulations for three proposals: (1) election of eleven board nominees, (2) ratification of KPMG LLP as independent auditor, and (3) advisory vote on named executive officer compensation. All three proposals passed with substantial majorities, making this a material governance event that affects investor understanding of board composition and auditor selection.
View raw filing on EDGAR →BlackRock registered up to 12,035,866 shares of common stock for issuance upon redemption of SubCo Units held by sellers of the HPS Investment Partners acquisition. The registration covers both closing-date consideration shares (7,606,927) and deferred consideration units (4,428,939) contingent on post-closing milestones. This is a dilutive equity issuance tied to an M&A transaction, with the prospectus supplement filed to register the shares for future redemption/exchange. While the HPS Transaction itself closed on July 1, 2025, this Item 8.01 disclosure addresses the registration mechanics for the equity consideration component, which is material to shareholders as it represents significant potential dilution.
View raw filing on EDGAR →This disclosure describes the consummation of Gores Holdings XI's initial public offering on June 24, 2026, raising $358.8 million in gross proceeds from the sale of 35.88 million units (including over-allotment), plus a concurrent private placement of 225,000 Class A shares to the sponsor for $2.25 million. While the IPO itself is a capital-raising event that would normally be classified as a dilutive_issuance, the filing is structured as Item 8.01 (Other Events) rather than Item 3.02, and the disclosure emphasizes the consummation of the IPO and trust account mechanics rather than the equity issuance per se. The event is material to investors as it establishes the company's capitalization and trust account structure, but the specific event type is ambiguous given the Item placement and the emphasis on the IPO completion rather than the equity issuance mechanics alone.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Erasca's June 26, 2026 annual meeting of stockholders, including the election of three Class II Directors (Alexander W. Casdin, Julie Hambleton, M.D., and Michael D. Varney, Ph.D.) and ratification of KPMG LLP as independent auditor. The filing presents vote tallies for each director nominee and the auditor ratification, confirming all matters passed. This is a standard shareholder vote results disclosure material to investors' understanding of board composition and audit oversight.
View raw filing on EDGAR →The exhibit discloses results of a shareholder vote at Rezolve Ai's Annual General Meeting held on June 30, 2026, in which shareholders "overwhelmingly approved" a capital reduction and share repurchase authority for up to $300 million. This is a direct disclosure of shareholder vote results on a material capital allocation matter, fitting the shareholder_vote_results taxonomy precisely. The materiality is clear: a $300 million buyback mandate is significant to investor assessment of capital strategy and shareholder returns.
View raw filing on EDGAR →This is a media release dated June 30, 2026, in which Algoma Steel provides forward-looking guidance for Q2 2026 financial results, including expected steel shipments (175,000–180,000 tons) and Adjusted EBITDA ($5–$15 million). While technically guidance rather than reported results, the disclosure of quarterly financial expectations in a press release format is functionally equivalent to an earnings release and would materially affect investor assessment of the company's near-term performance and operational trajectory.
View raw filing on EDGAR →Hanmi Pharmaceutical completed its acquisition of all outstanding common shares of Aptose Biosciences not already owned by Hanmi for C$2.41 per share (approximately USD $3.5 million aggregate consideration) pursuant to a statutory plan of arrangement approved by shareholders on March 31, 2026, and consummated on June 30, 2026. The transaction resulted in Aptose becoming a wholly owned subsidiary of Hanmi and delisting from the TSX.
View raw filing on EDGAR →Gulf Resources received a notice from Nasdaq on June 25, 2026 accepting a compliance plan to regain compliance with Nasdaq Listing Rule 5250(c)(1) following delinquency notifications for failure to timely file its Form 10-K and Form 10-Q. The filing explicitly states that if the Company fails to evidence compliance upon filing the delinquent reports, "Staff will notify the Company that its securities will be subject to delisting." This is a classic delisting-risk disclosure under Item 3.01, with material consequences for continued trading on Nasdaq.
View raw filing on EDGAR →The 6-K is dated 30 June 2026 (mid-year) and references a "Market release" exhibit (99.1), which typically accompanies interim or half-year financial results for foreign private issuers. The filing date aligns with a half-year reporting period. Without access to the exhibit content, the most probable classification is a periodic interim financial report, though the exhibit could alternatively contain an earnings release announcement or other material disclosure.
View raw filing on EDGAR →The Board approved an amendment to the Company's share repurchase program, extending it through June 30, 2027, expanding authorization to derivative transactions, and reducing the aggregate authorization from $250 million to $100 million. Share repurchases constitute a return of capital to shareholders and fall within the dividend_distribution category, which encompasses distributions and share-repurchase programs. The reduction in authorization and extension of the program are material capital allocation decisions affecting shareholder value.
View raw filing on EDGAR →The press release announces that Wetour Robotics has regained compliance with Nasdaq's minimum bid price requirement (Rule 5550(a)(2)) after receiving a deficiency notice on December 30, 2025. While the announcement is positive (compliance regained), the underlying event—the prior non-compliance and delisting risk—is material to investors. The disclosure explicitly references the deficiency letter, the 180-day compliance period, and the closure of the matter, which are hallmarks of delisting-risk disclosures under Item 3.01. The company's ability to maintain Nasdaq listing standards is a material concern flagged in the forward-looking statements.
View raw filing on EDGAR →The 6-K announces the appointment of four individuals—Mr. Xuan He, Ms. Xinyi Wei, Ms. Zhen Liao, and Ms. Yiwen Zhang—as executive directors of the Board, effective June 30, 2026. Mr. He also serves as chief financial officer. This is a material governance event involving the appointment of multiple senior officers to the board, expanding it from five to nine members with six executive directors and three independent directors.
View raw filing on EDGAR →